Last reviewed · How we verify

Abrocitinib 100 mg (abrocitinib-100-mg)

Pfizer · FDA-approved approved Quality 48/100

Abrocitinib 100 mg (generic name: abrocitinib-100-mg) is a Janus kinase inhibitor drug developed by Pfizer. It is currently FDA-approved for Moderate to severe atopic dermatitis in adults who have had an inadequate response or intolerance to one or more biologics, or who are candidates for systemic therapy, Moderate to severe atopic dermatitis in children aged 12 years and older who have had an inadequate response or intolerance to one or more biologics, or who are candidates for systemic therapy.

Abrocitinib 100 mg, developed by Pfizer Inc., is a marketed drug for moderate to severe atopic dermatitis. It has a mechanism of action that targets the JAK1 enzyme, which plays a key role in inflammation. The drug has shown clinical differentiation in treating patients who have had an inadequate response or intolerance to one or more biologics. Its commercial significance is evident in its high revenue of $21.2B. Abrocitinib has undergone 6 trials and has been published in 45 publications. The drug's pipeline developments are not specified. Overall, Abrocitinib is a significant addition to the treatment options for atopic dermatitis.

At a glance

Generic nameabrocitinib-100-mg
SponsorPfizer
Drug classJanus kinase inhibitor
TargetJAK1
Therapeutic areaImmunology
PhaseFDA-approved
Annual revenue284

Approved indications

Common side effects

Drug interactions

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results
SEC EDGARRevenue + earnings

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Abrocitinib 100 mg

What is Abrocitinib 100 mg?

Abrocitinib 100 mg (abrocitinib-100-mg) is a Janus kinase inhibitor drug developed by Pfizer, indicated for Moderate to severe atopic dermatitis in adults who have had an inadequate response or intolerance to one or more biologics, or who are candidates for systemic therapy, Moderate to severe atopic dermatitis in children aged 12 years and older who have had an inadequate response or intolerance to one or more biologics, or who are candidates for systemic therapy.

What is Abrocitinib 100 mg used for?

Abrocitinib 100 mg is indicated for Moderate to severe atopic dermatitis in adults who have had an inadequate response or intolerance to one or more biologics, or who are candidates for systemic therapy, Moderate to severe atopic dermatitis in children aged 12 years and older who have had an inadequate response or intolerance to one or more biologics, or who are candidates for systemic therapy.

Who makes Abrocitinib 100 mg?

Abrocitinib 100 mg is developed and marketed by Pfizer (see full Pfizer pipeline at /company/pfizer).

What is the generic name of Abrocitinib 100 mg?

abrocitinib-100-mg is the generic (nonproprietary) name of Abrocitinib 100 mg.

What drug class is Abrocitinib 100 mg in?

Abrocitinib 100 mg belongs to the Janus kinase inhibitor class. See all Janus kinase inhibitor drugs at /class/janus-kinase-inhibitor.

What development phase is Abrocitinib 100 mg in?

Abrocitinib 100 mg is FDA-approved (marketed).

What are the side effects of Abrocitinib 100 mg?

Common side effects of Abrocitinib 100 mg include Nausea, Gastrooesophageal reflux disease, Pruritus, Vomiting, Pyrexia, Alanine aminotransferase increased.

What is Abrocitinib 100 mg's annual revenue?

Abrocitinib 100 mg generated approximately $0.0B in annual revenue.

What does Abrocitinib 100 mg target?

Abrocitinib 100 mg targets JAK1 and is a Janus kinase inhibitor.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing